ArticleNeuropsychology2026
Utilizing intraindividual cognitive variability to predict progression in stage 2 neuronal synuclein disease.
Article in Neuropsychology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating the Contrasting Perspectives Between the Constrained Disorder Principle and Deterministic Optical Nanoscopy: Enhancing Information Extraction from Imaging of Complex Systems.Bioengineering (Basel, Switzerland) · 2026Article
Corrections and comments
- Update of
Authors and funding
8 authors.
Funding
Abstract
objectiveNeuronal synuclein disease (NSD) involves pathological α-synuclein presence and often dopaminergic dysfunction, initially preceding overt clinical symptoms. NSD-Integrated Staging System identifies Stage 2A (no dopaminergic dysfunction) and 2B (dopaminergic dysfunction) as prodromal phases marked by subtle clinical signs without functional impairment. Intraindividual variability/dispersion (IIV-D), reflecting the degree of spread in a person's performance across a battery of cognitive tasks, has emerged as a potential marker of early neurodegenerative changes. This study examined whether IIV-D differentiates NSD Stage 2 participants from healthy controls and predicts progression to more advanced NSD stages.
methodData from the Parkinson's Progression Markers Initiative were used to assess performance across 11 neuropsychological tests in 934 participants (832 Stage 2; 102 controls). IIV-D was primarily quantified using the total coefficient of variation (CoV) and a domain-specific attention/executive CoV. Secondary exploratory analyses examined total intraindividual standard deviation (i
resultsStage 2 participants exhibited significantly greater CoV (
conclusionsIIV-D, particularly CoV, may be a sensitive cognitive marker of early NSD and predict short-term disease progression. Measures of i
Identifiers
42721347What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.